Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single Construct Suppression and Replacement Gene Therapy for the Treatment of All CALM1-, CALM2-, and CALM3-Mediated Arrhythmia Disorders.

Circulation. Arrhythmia and electrophysiology - 1 Aug 2024

Hamrick Samantha K, Kim C S John, Tester David J, Gencarelli Manuela, Tobert Kathryn E, Gluscevic Martina, Ackerman Michael J

Abstract excerpt

BACKGROUND: CaM (calmodulin)-mediated long-QT syndrome is a genetic arrhythmia disorder (calmodulinopathies) characterized by a high prevalence of life-threatening ventricular arrhythmias occurring early in life. Three distinct genes (CALM1, CALM2, and CALM3) encode for the identical CaM protein. Conventional pharmacotherapies fail to adequately protect against potentially lethal cardiac events in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Action Potentials
Share to Calmodulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Heart Rate

Share to Induced Pluripotent Stem Cells

Share to Long QT Syndrome

Share to Myocytes, Cardiac

Share to RNA Interference

Source

Identifiers

PMID: 39069900
DOI: 10.1161/CIRCEP.123.012036

Genes

CALM2
CALM1
CALM3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single Construct Suppression and Replacement Gene Therapy for the Treatment of All CALM1-, CALM2-, and CALM3-Mediated Arrhythmia Disorders.PMID 39069900Read ↗

Antisense Oligonucleotide Therapy for CalmodulinopathySemantic proximity Read ↗

A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT SyndromeSemantic proximity Read ↗

Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation.Semantic proximity Read ↗

Calmodulinopathy: A Novel, Life-Threatening Clinical Entity Affecting the YoungSemantic proximity Read ↗

Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry.Semantic proximity Read ↗

Suppression-Replacement KCNQ1 Gene Therapy for Type 1 Long QT SyndromeSemantic proximity Read ↗

Novel calmodulin mutations associated with congenital long QT syndrome affect calcium current in human cardiomyocytes.Semantic proximity Read ↗

Generation of a human induced pluripotent stem cell line ZZUNEUi030-A from a female patient carrying a heterozygous CALM2 (c.395 A > T) mutation.Semantic proximity Read ↗

Calmodulinopathy: Functional Effects of CALM Mutations and Their Relationship With Clinical PhenotypesSemantic proximity Read ↗

Calmodulin Mutations Associated with Heart Arrhythmia: A Status ReportSemantic proximity Read ↗

Spectrum and Prevalence of <i>CALM1</i> -, <i>CALM2</i> -, and <i>CALM3</i> -Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome–Associated Calmodulin Missense Variant, E141GSemantic proximity Read ↗

Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.